Browse studies

Find your next paid study

7 recruiting studies matching your filters

A Phase II Prospective Study Evaluating Selective Depletion of CD45RA⁺ Naïve T Cells (TND) From Peripheral Blood Stem Cell Grafts for the Prevention of Graft-Versus-Host Disease in Older Patients With Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

This phase II trial tests how well removing CD45RA positive naive T cells works to prevent graft versus host disease in older patients undergoing standard of c…

Acute Biphenotypic LeukemiaAcute LeukemiaAcute Leukemia of Ambiguous Lineage+11 more

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT07819396

Phase 2

Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Tagraxofusp (SL-401) in Combination With HCVAD/Mini-CVD and VENETOCLAX

This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoc…

Blastic Plasmacytoid Dendritic Cell Neoplasm

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT04216524

Phase 2

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics

This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) wo…

Acute Leukemia of Ambiguous LineageAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+7 more

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT06013423

Phase 1

Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: *…

Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT03113643

Phase 1

Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)

This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leuk…

Juvenile Myelomonocytic LeukemiaRecurrent Acute Biphenotypic LeukemiaRecurrent Acute Undifferentiated Leukemia+26 more

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the op…

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Estimated

~$10 – $1,125

Immune Oncology Research InstituteNCT05430971

Phase 1

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications …

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more